Host: Joyce O'Shaughnessy, MD Hormone receptor-positive, HER2-negative cancer is the most common subtype of breast cancer. Initial treatment consists of surgery with or without radiotherapy or chemoradiotherapy, followed by adjuvant endocrine therapy for 5 to 10 years. Although endocrine therapy improves outcomes in these patients, recurrence is hi…

Host: Martha Kingman, DNP, FNP-C Guest: Susanne McDevitt, DNP, ACNP-BC This program focuses on early symptom identification and timely diagnosis in patients with pulmonary hypertension (PH). Learn how appropriate risk stratification can facilitate the effective management of PH. Our experts also stress the importance of asking the right questions a…

Guest: C. Brendan Montano, MD Guest: Anton P. Porsteinsson, MD Early diagnosis and management of agitation in Alzheimer’s disease (AAD) is part of a comprehensive treatment plan. How can you help caregivers recognize subtle signs of AAD to facility early treatment? Our experts have the answers you need!…

Host: Jean M. Elwing, MD Host: Nicholas Kolaitis, MD, MAS Guest: Katharine Clapham, MD Pulmonary Arterial Hypertension (PAH) requires a personalized, multidisciplinary approach, which is often lacking in remote regions due to limited access to specialized care and resources. The scarcity of specialized PH centers forces reliance on general practiti…

Host: Denis Hadjiliadis, MD, MHS, PhD Guest: Gregory S. Sawicki, MD, MPH Guest: Alexandra Wilson, MS, RDN, CDE Guest: Susanna A. McColley, MD Cystic Fibrosis (CF) care faces challenges from health disparities, limited access, and unintended bias, affecting patient outcomes. This CME program aims to equip healthcare professionals with the skills nee…

Host: David H. Ilson, MD, PhD Guest: Sunnie Kim, MD This educational activity delves into biomarker-driven strategies for first-line therapy in metastatic gastric and gastroesophageal junction (GEJ) cancers. Participants will explore the latest clinical trial data and emerging biomarkers that guide treatment decisions. Our experts emphasize selecti…

Host: Farrukh Abbas, MD Guest: Megan Conroy, MD, MA(Ed) Listen in as Farrukh Abbas, MD, FCCP, and Megan Conroy, MD, MAEd, FCCP, discuss the role of the care team in COPD diagnosis, recent changes in classifications and updates to the GOLD guidelines, how triple-inhaler therapies and biologics can be used to treat patients with COPD, and more. Since…

Guest: Gilberto de Lima Lopes, Jr, MD, MBA, FASCO Guest: Jyoti Patel, MD The MET pathway can be activated by MET exon 14 skipping mutations, gene amplification, or overexpression. Mutations within this pathway carry a poor prognosis for patients with non-small cell lung cancer (NSCLC). Early studies of MET tyrosine kinase inhibitors (TKIs) demonstr…

Host: Sara M. Tolaney, MD, MPH This Chairperson’s Perspective will provide an in-depth look at ADC-directed therapies for HR+/HER2-expressing metastatic breast cancer. Participants will explore current treatment options, emerging data, and best practices for selecting and sequencing therapies. The session will also cover strategies for managing adv…

Host: Christina Economides, MD Guest: Brian Howard, MD Guest: David N. Kenigsberg, MD, FACC Despite guideline-directed medical therapy, many patients with heart failure will continue to develop worsening symptoms and diminishing quality of life. Baroflex activation therapy (BAT) may be a treatment option for patients with heart failure with reduced…

Host: Matthew S. Davids, MD, MMSc This program addresses the educational needs for relapsed or refractory (R/R) B-cell leukemias and lymphomas, particularly chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and reveals crucial practice gaps. Key challenges include managing poor treatment responses and patient health deterioration, nec…

Host: Caroline Piatek, MD Guest: Irina Murakhovskaya, MD Warm autoimmune hemolytic anemia (wAIHA) is a rare condition characterized by the premature destruction of red blood cells mainly by pathogenic IgG optimally active at 37oC. Innovative targeted therapies to address wAIHA are emerging, and many are likely to greatly improve patient outcomes wh…

Host: Brian P. McDonough, MD, FAAFP Guest: Barry Greenberg, MD Guest: Melissa Mclenon, DNP, ACNP-BC Heart failure (HF) represents a significant burden on healthcare systems worldwide, with its prevalence steadily rising due to aging populations and increasing rates of comorbidities such as diabetes and chronic kidney disease. Despite advances in me…

Host: Neil Skolnik, MD Guest: Barry Greenberg, MD Guest: Trina Huynh, PharmD Guest: Jessica Lin, MPAP Guest: Melissa Mclenon, DNP, ACNP-BC Guest: Karina Brown, BSN, RN Heart failure (HF) represents a significant burden on healthcare systems worldwide, with its prevalence steadily rising due to aging populations and increasing rates of comorbidities…

Host: Brian P. McDonough, MD, FAAFP Guest: Barry Greenberg, MD Guest: Neil Skolnik, MD Guest: Karina Brown, BSN, RN Heart failure (HF) represents a significant burden on healthcare systems worldwide, with its prevalence steadily rising due to aging populations and increasing rates of comorbidities such as diabetes and chronic kidney disease. Despit…

Host: Neil Skolnik, MD Guest: Barry Greenberg, MD Guest: Karina Brown, BSN, RN Guest: Jessica Lin, MPAP Guest: Melissa Mclenon, DNP, ACNP-BC Heart failure (HF) represents a significant burden on healthcare systems worldwide, with its prevalence steadily rising due to aging populations and increasing rates of comorbidities such as diabetes and chron…

Host: Neil Skolnik, MD Guest: Barry Greenberg, MD Guest: Trina Huynh, PharmD Guest: Melissa Mclenon, DNP, ACNP-BC Heart failure (HF) represents a significant burden on healthcare systems worldwide, with its prevalence steadily rising due to aging populations and increasing rates of comorbidities such as diabetes and chronic kidney disease. Despite …

Host: Helena Yu, MD The treatment of EGFR-mutated advanced non-small-cell lung cancer (NSCLC) that has progressed on EGFR TKI therapy remains a clinical challenge, as traditional therapies have yielded only modest results. However, recent findings show that targeting HER3 can produce dramatically improved clinical outcomes. Data are rapidly emergin…

Host: Ritu Salani, MD, MBA This online MinuteCE program delves into the significance of HER2 as an actionable biomarker across various tumor types, emphasizing its implications for targeted therapies and clinical decision-making. Participants will evaluate emerging data on the efficacy of HER2-directed agents in advanced HER2-positive solid tumors …

Host: Ritu Salani, MD, MBA This online MinuteCE program delves into the significance of HER2 as an actionable biomarker across various tumor types, emphasizing its implications for targeted therapies and clinical decision-making. Participants will evaluate emerging data on the efficacy of HER2-directed agents in advanced HER2-positive solid tumors …

Host: Shubham Pant, MD, MBBS Host: Ritu Salani, MD, MBA This online MinuteCE program delves into the significance of HER2 as an actionable biomarker across various tumor types, emphasizing its implications for targeted therapies and clinical decision-making. Participants will evaluate emerging data on the efficacy of HER2-directed agents in advance…

Host: Ritu Salani, MD, MBA This online MinuteCE program delves into the significance of HER2 as an actionable biomarker across various tumor types, emphasizing its implications for targeted therapies and clinical decision-making. Participants will evaluate emerging data on the efficacy of HER2-directed agents in advanced HER2-positive solid tumors …

Host: Shubham Pant, MD, MBBS This online MinuteCE program delves into the significance of HER2 as an actionable biomarker across various tumor types, emphasizing its implications for targeted therapies and clinical decision-making. Participants will evaluate emerging data on the efficacy of HER2-directed agents in advanced HER2-positive solid tumor…

Host: Ritu Salani, MD, MBA This online MinuteCE program delves into the significance of HER2 as an actionable biomarker across various tumor types, emphasizing its implications for targeted therapies and clinical decision-making. Participants will evaluate emerging data on the efficacy of HER2-directed agents in advanced HER2-positive solid tumors …

Host: Shubham Pant, MD, MBBS This online MinuteCE program delves into the significance of HER2 as an actionable biomarker across various tumor types, emphasizing its implications for targeted therapies and clinical decision-making. Participants will evaluate emerging data on the efficacy of HER2-directed agents in advanced HER2-positive solid tumor…

Host: Shubham Pant, MD, MBBS Host: Ritu Salani, MD, MBA This online MinuteCE program delves into the significance of HER2 as an actionable biomarker across various tumor types, emphasizing its implications for targeted therapies and clinical decision-making. Participants will evaluate emerging data on the efficacy of HER2-directed agents in advance…

Host: Thomas Kipps, MD, PhD Determining the optimal treatment regimen for patients with chronic lymphocytic leukemia (CLL) has been a clinical challenge, especially since most patients are older than 70 years, present with significant coexisting comorbidities, and exhibit one or more common chromosomal alterations. However, outcomes in CLL are impr…

Host: Thomas Kipps, MD, PhD Host: William Wierda, MD, PhD Determining the optimal treatment regimen for patients with chronic lymphocytic leukemia (CLL) has been a clinical challenge, especially since most patients are older than 70 years, present with significant coexisting comorbidities, and exhibit one or more common chromosomal alterations. How…

Host: Thomas Kipps, MD, PhD Host: William Wierda, MD, PhD Determining the optimal treatment regimen for patients with chronic lymphocytic leukemia (CLL) has been a clinical challenge, especially since most patients are older than 70 years, present with significant coexisting comorbidities, and exhibit one or more common chromosomal alterations. How…

Host: William Wierda, MD, PhD Determining the optimal treatment regimen for patients with chronic lymphocytic leukemia (CLL) has been a clinical challenge, especially since most patients are older than 70 years, present with significant coexisting comorbidities, and exhibit one or more common chromosomal alterations. However, outcomes in CLL are im…

Host: Talha Munir, PhD Determining the optimal treatment regimen for patients with chronic lymphocytic leukemia (CLL) has been a clinical challenge, especially since most patients are older than 70 years, present with significant coexisting comorbidities, and exhibit one or more common chromosomal alterations. However, outcomes in CLL are improving…

Host: Thomas Kipps, MD, PhD Host: William Wierda, MD, PhD Determining the optimal treatment regimen for patients with chronic lymphocytic leukemia (CLL) has been a clinical challenge, especially since most patients are older than 70 years, present with significant coexisting comorbidities, and exhibit one or more common chromosomal alterations. How…

Host: William Wierda, MD, PhD Determining the optimal treatment regimen for patients with chronic lymphocytic leukemia (CLL) has been a clinical challenge, especially since most patients are older than 70 years, present with significant coexisting comorbidities, and exhibit one or more common chromosomal alterations. However, outcomes in CLL are im…

Host: Talha Munir, PhD Determining the optimal treatment regimen for patients with chronic lymphocytic leukemia (CLL) has been a clinical challenge, especially since most patients are older than 70 years, present with significant coexisting comorbidities, and exhibit one or more common chromosomal alterations. However, outcomes in CLL are improving…

Host: Thomas Kipps, MD, PhD Host: William Wierda, MD, PhD Determining the optimal treatment regimen for patients with chronic lymphocytic leukemia (CLL) has been a clinical challenge, especially since most patients are older than 70 years, present with significant coexisting comorbidities, and exhibit one or more common chromosomal alterations. How…

Host: Thomas Kipps, MD, PhD Determining the optimal treatment regimen for patients with chronic lymphocytic leukemia (CLL) has been a clinical challenge, especially since most patients are older than 70 years, present with significant coexisting comorbidities, and exhibit one or more common chromosomal alterations. However, outcomes in CLL are impr…

Host: Saad Z. Usmani, MD, MBA, FACP Guest: Joshua Richter, MD Guest: Ashley Steinberger, APP Release date: 8/15/2024 Expiration date: 8/15/2025 Estimated time to complete: 1.0 hour This activity is not accredited for CME/CE credit. This episode of Myeloma Matters reviews the latest data on bispecific antibody therapy for relapsed/refractory multipl…

Host: Justin Gainor, MD Host: Jacob Sands, MD The treatment landscape of non-small cell lung cancer (NSCLC) has dramatically changed over the past 20 years. In recent years, the discovery of targetable molecular alterations and the development of targeted therapies have dramatically changed the treatment outlook for NSCLC. Human epidermal growth fa…

Host: Lee P. Shulman, MD, FACMG, FACOG Guest: Ayman Al-Hendy, MD, PhD, FRCSC, FACOG, CCRP Guest: James A. Simon, MD, CCD, NCMP, IF, FACOG While both medical therapy and surgery often play a role in a woman’s journey with endometriosis, it is less clear how to best sequence these approaches to optimize a patient’s outcomes. Under what circumstances …

Host: Lee P. Shulman, MD, FACMG, FACOG Guest: Ayman Al-Hendy, MD, PhD, FRCSC, FACOG, CCRP Guest: Sawsan As-Sanie, MD GnRH antagonists have emerged as a viable first-line (or subsequent-line) medical therapy for the management of endometriosis. They have proven to be effective and safe, and their use avoids the flare response observed with GnRH agon…

Host: Lee P. Shulman, MD, FACMG, FACOG Guest: Linda Bradley, MD Guest: Melissa Simon, MD The use of validated patient questionnaires, notably the SF-36 and EHP-30 scales, can greatly hasten the suspicion for an endometriosis diagnosis. Coupled with shared decision-making, or SDM, this patient-centered process can help ensure therapeutic adherence. …

Host: Lee P. Shulman, MD, FACMG, FACOG Guest: Linda Bradley, MD Guest: Melissa Simon, MD Both provider- and patient-related healthcare disparities exist in the diagnosis and management of endometriosis. Many disparities derive from incorrect historical biases, while others are associated with social determinants of health, or SDOH. Join Drs. Lee Sh…

Host: Lee P. Shulman, MD, FACMG, FACOG Guest: Sawsan As-Sanie, MD Guest: Linda Bradley, MD Endometriosis is often called a public health crisis for women. The delay in diagnosis can be greater than 10 years, during which time women suffer many physical and psychosocial issues that negatively impact their quality of life. Join Drs. Lee Shulman, Saws…

Host: Kara B. Markham, MD Guest: Kenneth J. Moise Jr., MD Hemolytic disease of the fetus and newborn (HDFN) is an alloimmune disorder between the mother and fetus, one with significant risk for dire health consequences for both. Fortunately, a better understanding of the neonatal Fc receptor (FcRn) pathway along with the emergence of an inhibitor o…

Host: Josep Tabernero, MD, PhD Guest: Sara Lonardi, MD Guest: Zev A. Wainberg, MD Join us for a CME online broadcast replay of a live satellite symposium from ESMO GI 2024, where experts discuss strategies to overcome barriers to implementing a collaborative, biomarker-based approach in precision oncology for HER2+ GI cancers. Learn how to individu…

Guest: Clete A. Kushida, MD, PhD Guest: Michael J. Thorpy, MD The 7 episodes in this program will help you understand how to identify early signs and symptoms of narcolepsy to achieve a timely diagnosis and to then effectively manage this condition. Our experts focus on a well-rounded diagnostic and management approach to address not only the physi…

Guest: Clete A. Kushida, MD, PhD Guest: Michael J. Thorpy, MD The 7 episodes in this program will help you understand how to identify early signs and symptoms of narcolepsy to achieve a timely diagnosis and to then effectively manage this condition. Our experts focus on a well-rounded diagnostic and management approach to address not only the physi…

Guest: Clete A. Kushida, MD, PhD Guest: Michael J. Thorpy, MD The 7 episodes in this program will help you understand how to identify early signs and symptoms of narcolepsy to achieve a timely diagnosis and to then effectively manage this condition. Our experts focus on a well-rounded diagnostic and management approach to address not only the physi…

Guest: Clete A. Kushida, MD, PhD Guest: Michael J. Thorpy, MD The 7 episodes in this program will help you understand how to identify early signs and symptoms of narcolepsy to achieve a timely diagnosis and to then effectively manage this condition. Our experts focus on a well-rounded diagnostic and management approach to address not only the physi…

Guest: Clete A. Kushida, MD, PhD Guest: Michael J. Thorpy, MD The 7 episodes in this program will help you understand how to identify early signs and symptoms of narcolepsy to achieve a timely diagnosis and to then effectively manage this condition. Our experts focus on a well-rounded diagnostic and management approach to address not only the physi…